AN ACT

- 1 Providing for lead screening and related services, for health
- insurance coverage for lead screening and related diagnostic services and supplies and for duties of the Department of
- 4 Health.
- 5 The General Assembly of the Commonwealth of Pennsylvania
- 6 hereby enacts as follows:
- 7 Section 1. Short title.
- 8 This act shall be known and may be cited as the Childhood
- 9 Lead Testing and Protection Act.
- 10 Section 2. Declaration of policy.
- 11 The General Assembly finds and declares as follows:
- 12 (1) According to the Centers for Disease Control and
- Prevention, at least 4,000,000 households have children
- living in them who are being exposed to high levels of lead,
- a naturally occurring element that is toxic to humans when
- ingested or inhaled.
- 17 (2) There are approximately 500,000 children in the
- United States between one and five years of age with blood

- lead levels above five micrograms per deciliter ($\mu g/dL$), the reference level at which the Centers for Disease Control and Prevention recommends public health actions be initiated.
 - (3) Lead poisoning is most detrimental to children under72 months of age and expectant mothers.
 - (4) The effects of lead poisoning are not reversible.
- 7 (5) According to the department's 2015 Childhood Lead 8 Surveillance Annual Report, of the 859,311 children in this 9 Commonwealth under six years of age, only 140,147 children 10 were screened for blood lead levels. Of the 140,147 children 11 tested, 9,643 children had elevated blood lead levels.
- 12 (6) Complications from lead poisoning include the following:
- 14 (i) Developmental delays.
- 15 (ii) Brain damage.

4

5

6

- 16 (iii) Nervous system damage.
- 17 (iv) Memory loss.
- 18 (v) Abdominal pain.
- 19 (vi) Aggressive behavior.
- 20 (vii) Constipation.
- 21 (viii) Sleep problems.
- 22 (ix) Headaches.
- 23 (x) Irritability.
- 24 (xi) Loss of developmental skills in children.
- 25 (xii) Loss of appetite.
- 26 (xiii) Fatigue.
- 27 (xiv) High blood pressure.
- 28 (xv) Numbness or tingling in the extremities.
- 29 (xvi) Anemia.
- 30 (xvii) Kidney dysfunction.

- 1 (7) No safe blood lead level in children has been
- 2 identified.
- 3 Section 3. Definitions.
- 4 The following words and phrases when used in this act shall
- 5 have the meanings given to them in this section unless the
- 6 context clearly indicates otherwise:
- 7 "Birthing facility." An inpatient or ambulatory health care
- 8 facility licensed by the department that provides birthing and
- 9 newborn care services.
- "Blood lead level." A measure of lead in the blood, measured
- 11 in micrograms of lead per deciliter of whole blood (µg/dL).
- "Child." A child under 72 months of age who is a resident of
- 13 this Commonwealth.
- 14 "Department." The Department of Health of the Commonwealth.
- "Diagnostic blood lead level testing." Analysis of a blood
- 16 sample to determine quantitative blood lead levels for a sample:
- 17 (1) Obtained by venipuncture or capillary blood sampling
- 18 for the purpose of any of the following:
- (i) Confirming lead poisoning as a follow-up blood
- lead level test.
- 21 (ii) Diagnosing a child or expectant mother showing
- 22 signs or symptoms of lead poisoning.
- 23 (iii) Diagnosing a child or expectant mother
- suspected of having sustained a significant lead
- exposure.
- 26 (2) Analyzed in a laboratory licensed by the department
- 27 to perform the testing or in a laboratory of the department.
- 28 "Diagnostic evaluation." Obtaining and evaluating medical
- 29 history information, conducting a physical examination and
- 30 diagnostic blood lead level testing, identifying potential

- 1 sources of lead exposure and evaluating iron status.
- 2 "Government program." Any of the following:
- 3 (1) The children's health care program under Article
- 4 XXIII-A of the act of May 17, 1921 (P.L.682, No.284), known
- 5 as The Insurance Company Law of 1921.
- 6 (2) The Commonwealth's medical assistance program
- 7 established under the act of June 13, 1967 (P.L.31, No.21),
- 8 known as the Human Services Code.
- 9 "Health care practitioner." As defined in section 103 of the
- 10 act of July 19, 1979 (P.L.130, No.48), known as the Health Care
- 11 Facilities Act.
- "Insurance policy." An individual or group health insurance
- 13 policy, contract or plan issued by or through an insurer or a
- 14 government program that provides medical or health care coverage
- 15 by a health care facility or licensed health care provider. The
- 16 term does not include accident only, fixed indemnity, limited
- 17 benefit, credit, dental, specified disease, Civilian Health and
- 18 Medical Program of the Uniformed Services (CHAMPUS) supplement,
- 19 long-term care or disability income, workers' compensation or
- 20 automobile medical payment insurance.
- "Insurer." An entity or affiliate entity that issues an
- 22 insurance policy that is offered or governed under any of the
- 23 following:
- 24 (1) The act of May 17, 1921 (P.L.682, No.284), known as
- 25 The Insurance Company Law of 1921.
- 26 (2) The act of December 29, 1972 (P.L.1701, No.364),
- known as the Health Maintenance Organization Act.
- 28 (3) The act of May 18, 1976 (P.L.123, No.54), known as
- 29 the Individual Accident and Sickness Insurance Minimum
- 30 Standards Act.

- 1 (4) 40 Pa.C.S. Ch. 61 (relating to hospital plan
- 2 corporations).
- 3 (5) 40 Pa.C.S. Ch. 63 (relating to professional health
- 4 services plan corporations).
- 5 "Lead poisoning." A blood lead level that meets one of the
- 6 following criteria:
- 7 (1) A confirmed blood lead level greater than or equal
- 8 to 20 $\mu g/dL$ in a child or expectant mother.
- 9 (2) Two blood lead level samples of a child or expectant
- mother, separated by at least 90 days, but not more than 365
- days, which indicate a blood lead level greater than or equal
- 12 to 15 μ g/dL.
- "Lead screening-related services." Include:
- (1) Materials and supplies used to obtain blood
- specimens for quantitative blood lead level or erythrocyte
- protoporphyrin (EP) analysis.
- 17 (2) Laboratory analysis of submitted samples for
- 18 quantitative blood lead level or EP analysis.
- 19 (3) Evaluation of results obtained from laboratory
- 20 analysis of samples submitted for quantitative blood lead
- 21 level or EP analysis, as well as related consultation,
- referral and follow-up of potentially lead-poisoned children
- 23 and expectant mothers.
- "Screening test." A blood sample obtained either by
- 25 venipuncture or capillary blood sampling from an asymptomatic
- 26 child or expectant mother not known to be lead poisoned in order
- 27 to identify the child or expectant mother's risk of lead
- 28 poisoning.
- 29 Section 4. Screening.
- 30 (a) General rule. -- Screening tests shall be performed in

- 1 accordance with the following:
- 2 (1) Children shall receive a screening test in
- 3 accordance with the following schedule:
- 4 (i) Each child shall be screened at 12 months of age and 24 months of age.
- (ii) All children designated as high risk through a risk assessment evaluation promulgated by the department shall be screened annually from 12 months of age to 72 months of age.
- 10 (iii) More frequent screening tests for asymptomatic 11 children under 72 months of age may be completed upon 12 recommendation of a health care practitioner.
- 13 (2) All expectant mothers shall receive a screening test 14 as part of their prenatal care.
- 15 (b) Testing methods.--Health care practitioners shall ensure
- 16 that screening tests are conducted either by venipuncture or by
- 17 capillary blood sampling in accordance with department
- 18 regulation.
- 19 (c) Exception. -- If the parent or guardian of a child objects
- 20 in writing on the ground that a screening test conflicts with a
- 21 religious belief or practice, the screening test under
- 22 subsection (a) may not be performed.
- 23 Section 5. Health insurance coverage.
- 24 (a) General rule. -- An insurance policy shall provide
- 25 coverage for all of the following:
- 26 (1) Screening tests and lead-screening-related services
- for children under 72 months of age and expectant mothers.
- 28 (2) Diagnostic evaluations.
- 29 (b) Department duties. -- The department shall provide the
- 30 following services for children under 72 months of age and

- 1 expectant mothers who are not covered by a health insurance
- 2 policy:
- 3 (1) Screening tests and lead screening-related services.
- 4 (2) Diagnostic evaluations.
- 5 (c) Reimbursement.--The department shall not be required to
- 6 reimburse third parties for services under subsection (b) that
- 7 are not provided by the department.
- 8 (d) Applicability. -- This section shall apply to insurance
- 9 policies issued or entered into on or after the effective date
- 10 of this section.
- 11 Section 6. Materials.
- 12 (a) Educational and instructional materials. -- The department
- 13 shall distribute readily understandable information and
- 14 educational and instructional materials regarding lead
- 15 poisoning. The materials shall at a minimum explain the risk
- 16 factors associated with lead exposure and emphasize lead
- 17 screening and testing procedures, treatment of lead poisoning
- 18 and the requirements of this act. The materials shall be
- 19 provided to parents of newborns prior to discharge from a
- 20 hospital or birthing facility. If the birth takes place in a
- 21 setting other than a hospital or birthing facility, the
- 22 materials shall be provided by a health care practitioner who
- 23 assists at the birth.
- 24 (b) Acknowledgment statement. -- An acknowledgment statement
- 25 shall be signed by a parent of a newborn prior to discharge from
- 26 a hospital or birthing facility or after a birth that takes
- 27 place in a setting other than a hospital or birthing facility.
- 28 One copy of the acknowledgment statement shall be given to a
- 29 parent and one copy shall remain on file in the hospital or
- 30 birthing facility. Copies of acknowledgment statements signed by

- 1 parents of newborns in settings other than a hospital or
- 2 birthing facility shall be kept on file by the health care
- 3 practitioner who assists at the birth. The acknowledgment
- 4 statement shall be in a form as prescribed by the department.
- 5 (c) Distribution of materials. -- The information and
- 6 educational and instructional materials described in subsection
- 7 (a) shall be provided without cost by each hospital, birthing
- 8 facility or health care practitioner to a parent of each newborn
- 9 upon discharge from a hospital or birthing facility or after
- 10 births that take place in settings other than a hospital or
- 11 birthing facility.
- 12 (d) Liability. -- A hospital, birthing facility or health care
- 13 practitioner shall not be civilly or criminally liable for the
- 14 action or inaction of a parent with regard to lead exposure
- 15 pursuant to materials given to the parent relating to lead
- 16 exposure.
- 17 Section 7. Regulations.
- The department shall promulgate regulations as necessary to
- 19 implement the provisions of this act.
- 20 Section 8. Effective date.
- 21 This act shall take effect in 90 days.